Afasevikumab  (Synonyms: RG 7624; RO 5553110; NI-1401)

Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IL17A

Afasevikumab consisting of an N-terminal IL-17F specific moiety, a-C terminal moiety that binds both IL-17A and IL-17F, and a central portion binding human serum albumin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3605  [NCBI]

Q16552

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.065 kDa

1589503-30-9

Liquid

Colorless to light yellow

[Afasevikumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Afasevikumab on AHC2 biosensor, can bind IL-17A Protein, Human (HEK293, His, HY-P70527) with an affinity constant of <1.000E-11 M as determined in BLI assay.
• 
  Flow cytometric analysis of 1X10⁶ Jurkat cells with Afasevikumab (HY-P99424, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Andrea Chiricozzi, et al. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl). 2019 May 24;9:29-35.  [Content Brief]